Therapeutic effects of Δ9-THC and modafinil in a marmoset Parkinson model

European Neuropsychopharmacology

Volumn 18, Issue 5, 2008, Pages 383-389

  van Vliet, Sanneke A M ^a,b   Vanwersch, Raymond A P ^a   Jongsma, Marjan J ^a   Olivier, Berend ^b,c   Philippens, Ingrid H C H M ^a  

^a TNO   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Behavior; Delta 9 tetrahydrocannabinol; Hand eye coordination; Locomotor activity; Marmoset; Modafinil; MPTP; Parkinson's disease; Therapy

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ANTIPARKINSON AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; DRONABINOL; LEVODOPA; MODAFINIL; PSYCHOTROPIC AGENT; BENZHYDRYL DERIVATIVE; TETRAHYDROCANNABINOL;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EXPLORATORY BEHAVIOR; EYE HAND COORDINATION; FEMALE; INVOLUNTARY MOVEMENT; LOCOMOTION; MALE; MARMOSET; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RATING SCALE; SINGLE DRUG DOSE; SYMPTOM; ANIMAL; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; PARKINSONISM; PATHOPHYSIOLOGY;

ANIMALS; ANTIPARKINSON AGENTS; BEHAVIOR, ANIMAL; BENZHYDRYL COMPOUNDS; CALLITHRIX; DISEASE MODELS, ANIMAL; FEMALE; MALE; PARKINSONIAN DISORDERS; TETRAHYDROCANNABINOL;

EID: 40849130842     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2007.11.003     Document Type: Article

References (46)

1. Adler C.H., Caviness J.N., Hentz J.G., Lind M., and Tiede J. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease. Mov. Disord. 18 (2003) 287-293
2. Aigner T.G. Delta-9-tetrahydrocannabinol impairs visual recognition memory but not discrimination learning in rhesus monkeys. Psychopharmacology 95 (1988) 507-511
3. Bastuji H., and Jouvet M. Successful treatment of idiopathic hypersomnia and narcolepsy with modafinil. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 12 (1988) 695-700
4. Brotchie J.M. CB1 cannabinoid signaling in Parkinson's disease. Curr. Opin. Pharmacol. 3 (2003) 54-61
5. Castiello U., Bennett K.M., Bonfiglioli C., and Peppard R.F. The reach-to-grasp movement in Parkinson's disease before and after dopaminergic medication. Neuropsychologia 38 (2000) 46-59
6. Croxford J.L. Therapeutic potential of cannabinoids in CNS disease. CNS Drugs 17 (2003) 179-202
7. Daley J., Turner R., Bliwise D., and Rye D. Nocturnal sleep and daytime alertness in the MPTP-treated primate. Sleep 22 (1999) S218-S219
8. Di Marzo V., Hill M.P., Bisogno T., Crossman A.R., and Brotchie J.M. Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB J. 14 (2000) 1432-1438
9. Di Monte D.A., McCormack A., Petzinger G., Janson A.M., Quik M., and Langston W.J. Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model. Mov. Disord. 15 (2000) 459-466
10. Fernandez-Espejo E., Caraballo I., de Fonseca F.R., El Banoua F., Ferrer B., Flores J.A., and Galan-Rodriguez B. Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism. Neurobiol. Dis. 18 (2005) 591-601
11. Ferraro L., Antonelli T., O'Connor W.T., Tanganelli S., Rambert F.A., et al. The antinarcoleptic drug modafinil increases glutamate release in thalamic areas and hippocampus. Neuroreport 8 (1997) 2883-2887
12. Ferraro L., Antonelli T., O'Connor W.T., Tanganelli S., Rambert F.A., and Fuxe K. The effects of modafinil on striatal, pallidal and nigral GABA and glutamate release in the conscious rat: evidence for a preferential inhibition of striato-pallidal GABA transmission. Neurosci. Lett. 253 (1998) 135-138
13. Fox S.H., Kellett M., Moore A.P., Crossman A.R., and Brotchie J.M. Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia. Mov. Disord. 17 (1) (2002) 145-9
14. García-Arencibia M., González S., De Lago E., Ramos J.A., Mechoulam R., et al. Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent. Brain Res. 1134 (2007) 162-170
15. Gentilucci M., and Negrotti A. Planning and executing an action in Parkinson's disease. Mov. Disord. 14 (1999) 69-79
16. Gerdeman G., and Lovinger D.M. CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. J. Neurophysiol. 85 (2001) 468-471
17. Gerlach M., Riederer P., Przuntek H., and Youdim M.B.H. MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. Eur. J. Pharm. 208 (1991) 273-286
18. Green P.M., and Stillman M.J. Narcolepsy. Signs, symptoms, differential diagnosis, and management. Arch. Fam. Med. 7 (1998) 472-478
19. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin. Pharmacokinet. 42 (2003) 327-360
20. Guy W. ECDEU assessment manual for psychopharmacology (1976), U.S. Department of Health, Education and Welfare, Washington D.C. 534-537
21. Happe S., Pirker W., Sauter C., Klosch G., and Zeitlhofer J. Successful treatment of excessive daytime sleepiness in Parkinson's disease with modafinil. J. Neurol. 248 (2001) 632-634
22. Howlett A.C., Barth F., Bonner T.I., Cabral G., Casellas P., Devane W.A., et al. International union of pharmacology XXV11 Classification of cannabinoid receptors. Pharmacol. rev. 54 (2002) 161-202
23. Jenner P., and Marsden C.D. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease. J. Neural Transm., Suppl. 20 (1986) 11-39
24. Jenner P., Zeng B.Y., Smith L.A., Pearce R.K., Tel B., Chancharme L., and Moachon G. Antiparkinsonian and neuroprotective effects of modafinil in the MPTP-treated common marmoset. Exp. Brain Res. 133 (2000) 178-188
25. Katzenschlager R., Manson A.J., Evans A., Watt H., and Lees A.J. Low dose quetiapine for drug induced dyskinesias in Parkinson's disease: a double blind cross over study. J Neurol Neurosurg Psychiatry 75 (2004) 295-297
26. Lang A.E., and Lozano A.M. Parkinson's disease. Second of two parts. N. Engl. J. Med. 339 (1998) 1130-1143
27. Lastres-Becker I., Molina-Holgado F., Ramos J.A., Mechoulam R., and Fernández-Ruiz J. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol. Dis. 19 (2005) 96-107
28. Lastres-Becker I., Cebeira M., de Ceballos M.L., Zeng B.Y., Jenner P., Ramos J.A., and Fernandez-Ruiz J.J. Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets. Eur. J. Neurosci. 14 (2001) 1827-1832
29. Maneuf Y.P., Crossman A.R., and Brotchie J.M. The cannabinoid receptor agonist WIN 55,212-2 reduces D2, but not D1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson's disease. Exp. Neurol. 148 (1997) 265-270
30. Metz G.A., Farr T., Ballermann M., and Whishaw I.Q. Chronic levodopa therapy does not improve skilled reach accuracy or reach range on a pasta matrix reaching task in 6-OHDA dopamine-depleted (hemi-Parkinson analogue) rats. Eur. J. Neurosci. 14 (2001) 27-37
31. Meschler J.P., Howlett A.C., and Madras B.K. Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-treated non-human primates. Psychopharmacology 156 (2001) 79-85
32. Nieves A.V., and Lang A.E. Treatment of excessive daytime sleepiness in patients with Parkinson's disease with modafinil. Clin. Neuropharmacol. 25 (2002) 111-114
33. Perlin E., Smith C.G., Nichols A.I., Almirez R., Flora K.P., Cradock J.C., and Peck C.C. Disposition and bioavailability of various formulations of tetrahydrocannabinol in the rhesus monkey. J. Pharm. Sci. 74 (1985) 171-174
34. Philippens I.H., Melchers B.P., Roeling T.A., and Bruijnzeel P.L. Behavioral test systems in marmoset monkeys. Behav Res Methods Instrum Comput 32 (2000) 173-179
35. Romero J., Lastres-Becker I., de Miguel R., Berrendero F., Ramos J.A., and Fernandez-Ruiz J. The endogenous cannabinoid system and the basal ganglia. biochemical, pharmacological, and therapeutic aspects. Pharmacol. Ther. 95 (2002) 137-152
36. Sanudo-Pena M.C., Patrick S.L., Khen S., Patrick R.L., Tsou K., and Walker J.M. Cannabinoid effects in basal ganglia in a rat model of Parkinson's disease. Neurosci. Lett. 248 (2001) 171-174
37. Sieradzan K.A., Fox S.H., Hill M., Dick J.P., Crossman A.R., and Brotchie J.M. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology 57 (2001) 2108-2111
38. Silverdale M.A., McGuire S., McInnes A., Crossman A.R., and Brotchie J.M. Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease. Exp. Neurol. 169 (2001) 400-406
39. Simon P., Hemet C., Ramassamy C., and Costentin J. Non-amphetaminic mechanism of stimulant locomotor effect of modafinil in mice. Eur. Neuropsychopharmacol. 5 (1995) 509-514
40. Van der Stelt M., Fox S.H., Hill M., Crossman A.R., Petrosino S., Di Marzo V., and Brotchie J.M. A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease. FASEB J. 19 (2005) 1140-1142
41. Van Vliet S.A., Jongsma M.J., Vanwersch R.A., Olivier B., and Philippens I.H. Behavioral effects of modafinil in marmoset monkeys. Psychopharmacology 185 (2006) 433-440
42. Venderova K., Ruzicka E., Vorisek V., and Visnovsky P. Survey on cannabis use in Parkinson's disease: subjective improvement of motor symptoms. Mov. Disord. 19 (2004) 1102-1106
43. Ward C.P., Harsh J.R., York K.M., Stewart K.L., and McCoy J.G. Modafinil facilitates performance on a delayed nonmatching to position swim task in rats. Pharmacol. Biochem. Behav. 78 (2004) 735-741
44. Wichmann T., and DeLong M.R. Models of basal ganglia function and pathophysiology of movement disorders. Neurosurg. Clin. N. Am. 9 (1998) 223-236
45. Wisor J.P., and Eriksson K.S. Dopaminergic-adrenergic interactions in the wake promoting mechanism of modafinil. Neuroscience 132 (2005) 1027-1034
46. Wolthuis O.L., Groen B., and Philippens I.H. A simple automated test to measure exploratory and motor activity of marmosets. Pharmacol. Biochem. Behav. 47 (1994) 879-881